Bright Minds Biosciences Inc. (DRUG)

NCM – Real Time Price. Currency in USD

84.65

-1.90 (-2.20%)

At close: May 12, 2026, 4:00 PM EDT

25.02.2026

Bright Minds Biosciences to Present at Upcoming Conferences

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:

09.01.2026

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) today closed its recently announced public offering of 1,945,000 common shares in the capital of the Company (the “Common Shares”) at a price of US$90.00 per Common Share for gross proceeds of US$175,050,000 (the “Offering”). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities sold in this Offering were offered by Bright Minds.

08.01.2026

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the pricing of its previously announced public offering of 1,945,000 common shares in the capital of the Company (the “Common Shares”) at a price of $90.00 per Common Share for anticipated gross proceeds of $175,050,000 (the “Offering”). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities being sold in this Offering are being offered by Bright Minds.

07.01.2026

Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating

Bright Minds Biosciences remains a "Strong Buy" after positive phase 2 data for BMB-101 in drug-resistant epilepsies. DRUG's BMB-101 achieved -73.1% and -63.3% median seizure reductions in Absence Epilepsy and DEE cohorts, respectively. Multiple 2026 catalysts include additional phase 2 data, phase 3 trial initiation, and a phase 2 PWS study for BMB-101.

06.01.2026

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the launch of a public offering of common shares in the capital of the Company (the “Common Shares”) and, in lieu of Common Shares to investors that so choose, pre-funded warrants (the “Pre-Funded Warrants”) to purchase Common Shares, for aggregate gross proceeds of US$100 million (the “Offering”). In connection with the Offering, the Company intends to grant to the underwriters, a 30-day option to purchase up to an additional 15% of the Common Shares issued in the Offering.

06.01.2026

New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday

Bright Minds Biosciences Inc. (NASDAQ: DRUG) stock is trading higher on Tuesday after the company shared topline results from its Phase 2 BREAKTHROUGH trial of BMB-101 for drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE).

06.01.2026

Bright Mind Biosciences shares surge on positive epilepsy drug trial results

Shares of Bright Minds Biosciences Inc (NASDAQ: DRUG, CSE:DRUG) jumped almost 25% after the company announced positive topline results from its Phase 2 BREAKTHROUGH clinical trial of BMB-101 in adults with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE). The open-label, multicenter study evaluated 24 patients, exceeding the original target of 20, and included both a 4-week baseline period and subsequent titration and maintenance phases.

Videos

No Data

There is no data to display

Press releases

09.01.2026

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

08.01.2026

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

06.01.2026

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

06.01.2026

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (“Bright Minds” or the “Company”), a clinical-stage biotechnology company focused on developing highly selective 5-HT receptor agonists for neurological and psychiatric disorders, today announced positive and significant topline results from its Phase 2 BREAKTHROUGH clinical trial evaluating BMB-101, a selective 5-HT2C biased agonist, in adult patients with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies. The study met its primary efficacy endpoints in both cohorts, demonstrating robust seizure reduction with a favorable safety and tolerability profile.

Bright Minds Biosciences Inc. (DRUG)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Bright Minds Biosciences Inc. (DRUG)

Bright Minds Biosciences to Present at Upcoming Conferences

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday

Bright Mind Biosciences shares surge on positive epilepsy drug trial results

Videos

No Data

Press releases

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

Bright Minds Biosciences to Present at Upcoming Conferences

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday

Bright Mind Biosciences shares surge on positive epilepsy drug trial results

Videos

No Data

Press releases

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

Search stocks

Bright Minds Biosciences Inc. (DRUG)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Bright Minds Biosciences Inc. (DRUG)

Bright Minds Biosciences to Present at Upcoming Conferences

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday

Bright Mind Biosciences shares surge on positive epilepsy drug trial results

Videos

No Data

Press releases

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

Bright Minds Biosciences to Present at Upcoming Conferences

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday

Bright Mind Biosciences shares surge on positive epilepsy drug trial results

Videos

No Data

Press releases

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)